Skip to main content

Table 4 Adjusting effects for possible confounders - SVR, HIV-positive patients

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

 

SVR

No SVR

Uni-variate

Multi-variate

Multivariate

 

n = 64

n = 54

p-value

p-value

Odds-ratio (95% CI)

Age [years]

40 (27 - 54)

41 (27 - 48)

0.566

-

-

Male sex [%]

75

78

0.662

-

-

Transm. risk IVDU [%]

20

30

0.709

-

-

HCV GT 1 or 4 [%]

50

76

0.002

0.001

0.2 (0.1 - 0.5)

HCVRNA ≥ 5 × 105 IU/ml[%]

42

63

0.014

0.009

0.3 (0.1 - 0.7)

ALT [IU/l]

63 (19 - 190)

80 (25 - 250)

0.368

-

-

Weight adapted RBV [%]

88

73

0.237

-

-

Tx duration 48 wks [%]

47

27

0.309

-

-

Enrollment period [%]

    2002 - 2004

56

67

0.253

-

-

    2005 - 2007

44

32

   

Treatment arm [%]

    B (no HAART)

44

39

   

    C1 (NRTI-cont.)

33

52

0.047

0.025

0.3 (0.1 - 0.9)*

    C2 (NRTI free)

23

9

   

HIV-RNA [copies/ml, log 10 ]

1.7 (1.7 - 4.8)

1.7 (1.7 - 4.8)

0.372

-

 

CD4-cellcount

     

    [/μl]

487 (236 - 1042)

542 (222 - 831)

0.828

-

 

    [%]

27 (15 - 41)

26 (12 - 41)

0.364

-

 

Anemia [%]

    Grade 1/2

11

11

1.000

.

 

    Grade 3/4

-

-

   

Leucopenia [%]

    Grade 1/2

47

41

0.578

-

 

    Grade 3/4

9

7

0.753

  

Thrombocytopenia [%]

    Grade 1/2

47

43

0.712

-

 

    Grade 3/4

5

6

1.000

  

Clinical adverse events [%]

    Grade 1/2

67

69

1.000

-

 

    Grade 3/4

11

13

0.781

  

Dose reduction PegIFN [%]

11

9

1.000

  

Dose reduction RBV [%]

13

20

0.215

-

 

Treatm. discont. AEs [%]

5

24

0.003

0.004

0.1 (0 - 0.5)

  1. Data shown as percent of patientsor median (95% range); *treatment arm C1 compared to B and C2 (reference) SVR sustained virological response, IVDU intravenous drug abuse, GT HCV genotype; ALT serum alanine aminotransferase, RBV ribavirin, Tx Treatment, wks weeks, NRTI nucleos(t)ide reverse transcriptase inhibitor, Treatment discont. AEs Treatment discontinuation due to adverse events.